Literature DB >> 15028353

Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients.

Fabio M Pulcinelli1, Pasquale Pignatelli, Andrea Celestini, Silvia Riondino, Pier Paolo Gazzaniga, Francesco Violi.   

Abstract

OBJECTIVES: We sought to investigate, during a two-year follow-up period, the effects of aspirin on platelet aggregation.
BACKGROUND: The platelets of patients given aspirin may be less sensitive to antiplatelet treatment, although the extent of such phenomenon over long-term follow-up is unclear.
METHODS: Adenosine diphosphate (ADP) and collagen-induced platelet aggregation was periodically monitored before and after 2, 6, 12, and 24 months of treatment with aspirin (n = 150) or ticlopidine (n = 80) in patients matched for gender, age, and risk factors for atherothrombosis.
RESULTS: Compared with baseline values, two months of aspirin treatment significantly inhibited platelet aggregation; thereafter, this inhibitory effect progressively decreased. At 24-month follow-up, collagen-induced platelet aggregation was significantly higher than that observed at two months (p < 0.05); a more pronounced difference was observed when collagen-induced lag phase was considered (p < 0.01). Restoration of platelet aggregation was less evident when ADP was used as an agonist. Conversely, the inhibition induced by ticlopidine was constant throughout follow-up with both agonists.
CONCLUSIONS: The study demonstrates that a long-term treatment with aspirin is associated with a progressive reduction in platelet sensitivity to this drug.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15028353     DOI: 10.1016/j.jacc.2003.08.062

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  29 in total

1.  Aspirin treatment failure and the risk of recurrent stroke and death among patients with ischemic stroke.

Authors:  Alexandros L Georgiadis; Steve M Cordina; Gabriela Vazquez; Nauman Tariq; M Fareed K Suri; Kamakshi Lakshminarayan; Harold P Adams; Adnan I Qureshi
Journal:  J Stroke Cerebrovasc Dis       Date:  2011-08-10       Impact factor: 2.136

2.  The variability of platelet response to aspirin and clopidogrel: revisiting the Caprie, Cure, Credo, and Match trials.

Authors:  Robert I Myers
Journal:  Proc (Bayl Univ Med Cent)       Date:  2005-10

Review 3.  Optimal duration of antiplatelet therapy in recipients of coronary drug-eluting stents.

Authors:  Marco Zimarino; Giulia Renda; Raffaele De Caterina
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Persistent high on-treatment platelet reactivity in acute coronary syndrome.

Authors:  Donald R Lynch; Farooq H Khan; Dhananjay Vaidya; Marlene S Williams
Journal:  J Thromb Thrombolysis       Date:  2012-04       Impact factor: 2.300

5.  Optimal Duration of Aspirin Plus Clopidogrel After Ischemic Stroke or Transient Ischemic Attack.

Authors:  Hammad Rahman; Safi U Khan; Fahad Nasir; Tehseen Hammad; Michael A Meyer; Edo Kaluski
Journal:  Stroke       Date:  2019-04       Impact factor: 7.914

Review 6.  Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions.

Authors:  Anetta Undas; Kathleen E Brummel-Ziedins; Kenneth G Mann
Journal:  Blood       Date:  2006-12-05       Impact factor: 22.113

7.  Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapy.

Authors:  Deepak Voora; Thomas L Ortel; Joseph E Lucas; Jen-Tsan Chi; Richard C Becker; Geoffrey S Ginsburg
Journal:  J Thromb Thrombolysis       Date:  2012-04       Impact factor: 2.300

Review 8.  Role of Aspirin in Breast Cancer Survival.

Authors:  Wendy Y Chen; Michelle D Holmes
Journal:  Curr Oncol Rep       Date:  2017-07       Impact factor: 5.075

9.  Response variability to aspirin and one-year prediction of vascular events in patients with stable coronary artery disease.

Authors:  Faouzi Addad; Tahar Chakroun; Fatma Abderazek; Mohamed Ben-Farhat; Sonia Hamdi; Zohra Dridi; Habib Gamra; Mohsen Hassine; Meyer M Samama; Ismail Elalamy
Journal:  J Thromb Thrombolysis       Date:  2010-01       Impact factor: 2.300

10.  Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease.

Authors:  A R Muir; M F McMullin; C Patterson; P P McKeown
Journal:  Heart       Date:  2008-08-12       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.